FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2565656857> ?p ?o ?g. }

• W2565656857 endingPage "3101" @default.
• W2565656857 startingPage "3101" @default.
• W2565656857 abstract "3101 Background: ON 01910.Na (ON) is a novel multitargeted inhibitor of several regulatory pathways including polo-like kinase 1 (Plk1) and PI-3 kinases, with synergistic preclinical activity when combined with gemcitabine (G; Jimeno et al, 2008, 2009), prompting a phase I clinical evaluation. Methods: Patients (pts) had histologically confirmed solid tumors refractory to standard therapy. G was administered as a 30-min infusion on days 1, 8 and 15 of a 28-day cycle. ON was administered as a 2-h infusion on days 1, 4, 8, 11, 15, and 18. Assessments included safety, response, pharmacokinetic interaction studies at the MTD, and pharmacodynamics in tumor at the MTD. The MTD was further confirmed in an expansion cohort enriched in advanced pancreatic cancer pts. Results: Thirty-six pts (median age 61; median ECOG PS 1) received a median of 3 cycles (6 pts ongoing) at 5 dose levels: (G/ON mg/m2: 750/600 n=6; 1,000/600 n=5; 750/1,200 n=3; 1,000/1,200 n=3; 1,000/1,800 n=19). Only those toxicities that were expected from G were observed in patients treated with the combination, and included thrombocytopenia, neutropenia, elevated AST/ALT, nausea, vomiting, and fatigue. One DLT was documented (death at Day 18 at the 1,800 mg/m2 ON dose). Antitumor activity was seen in one G-pretreated Hodgkin lymphoma pt (PR), 2 ovarian cancer pts (1 G-pretreated with 50% decrease in CA125; 1 G-naïve with 50% decrease in CA125 and 12% tumor regression), one NSCLC pt (SD at 24 weeks) and one thymic cancer pt (PR at 32 weeks). Additionally, 18 advanced pancreatic cancer (PC) pts were enrolled. Tumor regression (including one confirmed PR in a G-pretreated pt) was noted in 7/13 evaluable pts and CA 19-9 decrease in 8/13 pts. Median progression-free survival was 19 weeks and overall survival 48 weeks at 1,200 and 1,800 mg/m2 ON doses (n=12) in the subset of 16 metastatic PC pts, 11 of whom were previously treated with G. Conclusions: ON 01910.Na 1,800 mg/m2 and gemcitabine combination is well tolerated. Anti-tumor activity in G-pretreated pts with advanced PC provide the rationale for a phase II evaluation in metastatic PC pts. Final results will be presented and molecular data including PI3K mutation status." @default.
• W2565656857 created "2017-01-06" @default.
• W2565656857 creator A5003463083 @default.
• W2565656857 creator A5007992309 @default.
• W2565656857 creator A5019151403 @default.
• W2565656857 creator A5025646273 @default.
• W2565656857 creator A5027427370 @default.
• W2565656857 creator A5033199189 @default.
• W2565656857 creator A5035986034 @default.
• W2565656857 creator A5041114807 @default.
• W2565656857 creator A5078259926 @default.
• W2565656857 date "2011-05-20" @default.
• W2565656857 modified "2023-10-14" @default.
• W2565656857 title "Final results of a phase I study of the combination of a novel cell cycle inhibitor ON 01910.Na with gemcitabine in patients with advanced pancreatic and other solid tumors." @default.
• W2565656857 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.3101" @default.
• W2565656857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28022758" @default.
• W2565656857 hasPublicationYear "2011" @default.
• W2565656857 type Work @default.
• W2565656857 sameAs 2565656857 @default.
• W2565656857 citedByCount "2" @default.
• W2565656857 countsByYear W25656568572012 @default.
• W2565656857 countsByYear W25656568572014 @default.
• W2565656857 crossrefType "journal-article" @default.
• W2565656857 hasAuthorship W2565656857A5003463083 @default.
• W2565656857 hasAuthorship W2565656857A5007992309 @default.
• W2565656857 hasAuthorship W2565656857A5019151403 @default.
• W2565656857 hasAuthorship W2565656857A5025646273 @default.
• W2565656857 hasAuthorship W2565656857A5027427370 @default.
• W2565656857 hasAuthorship W2565656857A5033199189 @default.
• W2565656857 hasAuthorship W2565656857A5035986034 @default.
• W2565656857 hasAuthorship W2565656857A5041114807 @default.
• W2565656857 hasAuthorship W2565656857A5078259926 @default.
• W2565656857 hasConcept C111113717 @default.
• W2565656857 hasConcept C112705442 @default.
• W2565656857 hasConcept C121332964 @default.
• W2565656857 hasConcept C121608353 @default.
• W2565656857 hasConcept C126322002 @default.
• W2565656857 hasConcept C142424586 @default.
• W2565656857 hasConcept C2777063308 @default.
• W2565656857 hasConcept C2780210213 @default.
• W2565656857 hasConcept C2780258809 @default.
• W2565656857 hasConcept C2780580376 @default.
• W2565656857 hasConcept C2780852908 @default.
• W2565656857 hasConcept C29730261 @default.
• W2565656857 hasConcept C71924100 @default.
• W2565656857 hasConcept C87355193 @default.
• W2565656857 hasConcept C90924648 @default.
• W2565656857 hasConcept C98274493 @default.
• W2565656857 hasConceptScore W2565656857C111113717 @default.
• W2565656857 hasConceptScore W2565656857C112705442 @default.
• W2565656857 hasConceptScore W2565656857C121332964 @default.
• W2565656857 hasConceptScore W2565656857C121608353 @default.
• W2565656857 hasConceptScore W2565656857C126322002 @default.
• W2565656857 hasConceptScore W2565656857C142424586 @default.
• W2565656857 hasConceptScore W2565656857C2777063308 @default.
• W2565656857 hasConceptScore W2565656857C2780210213 @default.
• W2565656857 hasConceptScore W2565656857C2780258809 @default.
• W2565656857 hasConceptScore W2565656857C2780580376 @default.
• W2565656857 hasConceptScore W2565656857C2780852908 @default.
• W2565656857 hasConceptScore W2565656857C29730261 @default.
• W2565656857 hasConceptScore W2565656857C71924100 @default.
• W2565656857 hasConceptScore W2565656857C87355193 @default.
• W2565656857 hasConceptScore W2565656857C90924648 @default.
• W2565656857 hasConceptScore W2565656857C98274493 @default.
• W2565656857 hasIssue "15_suppl" @default.
• W2565656857 hasLocation W25656568571 @default.
• W2565656857 hasOpenAccess W2565656857 @default.
• W2565656857 hasPrimaryLocation W25656568571 @default.
• W2565656857 hasRelatedWork W1989791046 @default.
• W2565656857 hasRelatedWork W2071442044 @default.
• W2565656857 hasRelatedWork W2074629895 @default.
• W2565656857 hasRelatedWork W2227061539 @default.
• W2565656857 hasRelatedWork W2378945660 @default.
• W2565656857 hasRelatedWork W2393063064 @default.
• W2565656857 hasRelatedWork W2395279311 @default.
• W2565656857 hasRelatedWork W2405907591 @default.
• W2565656857 hasRelatedWork W2479179615 @default.
• W2565656857 hasRelatedWork W3193935636 @default.
• W2565656857 hasVolume "29" @default.
• W2565656857 isParatext "false" @default.
• W2565656857 isRetracted "false" @default.
• W2565656857 magId "2565656857" @default.
• W2565656857 workType "article" @default.